Supplementary Material 35 Cost effectiveness scenario analysis – no within-trial cost or QALYs differences between arms

	Costs (95% CI) [P(most costly)]	QALYs (95% CI) [P(most effective)]	ICER	Incremental net health benefit (95% CI) k=£15,000 [Probability of being cost-effective]	k=£20,000	k=£30,000
Control	£587.42 (473.28, 738.54) [0]	17.79532 (17.77548, 17.81529) [0.003]		- - [0.229]	- - [0.075]	- - [0.025]
SWAL only	£668.01 (553.87, 819.13) [0.041]	17.80111 (17.78078, 17.82037) [0.301]	£13,913.89	0 (-0.004, 0.004) [0.343]	0.002 (-0.002, 0.006) [0.419]	0.003 (-0.001, 0.007) [0.411]
SWAL plus desk	£815.40 (698.7, 950.02) [0.959]	17.80913 (17.79109, 17.82999) [0.699]	£18,382.38	-0.001 (-0.031, 0.032) [0.428]	0.002 (-0.027, 0.035) [0.506]	0.006 (-0.023, 0.037) [0.564]